Viking Therapeutics (VKTX) Other financing activities (2014 - 2023)

Viking Therapeutics has disclosed Other financing activities across 8 years of filings, most recently posting $37000.0 for Q1 2023.

• Other financing activities for Q1 2023 came in at $37000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $56000.0 (changed N/A YoY), and the FY2022 annual result was $22000.0, down 52.17% from the prior year.
• Other financing activities came in at $37000.0 for Q1 2023 at Viking Therapeutics, up from $19000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $37000.0 in Q1 2023 to a low of $7000.0 in Q4 2019.
• The 3-year median for Other financing activities is $19000.0 (2021), against an average of $21000.0.
• Peak annual rise in Other financing activities reached 97.53% in 2019, while the deepest fall reached 97.53% in 2019.
• Viking Therapeutics' Other financing activities stood at $7000.0 in 2019, then soared by 171.43% to $19000.0 in 2021, then jumped by 94.74% to $37000.0 in 2023.
• The last three Other financing activities figures came in at $37000.0 (Q1 2023), $19000.0 (Q4 2021), and $7000.0 (Q4 2019), per Business Quant data.